Bio-Path Stock Forecast, Price & News

+0.15 (+2.88 %)
(As of 09/16/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume65,682 shs
Average Volume1.38 million shs
Market Capitalization$37.24 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

Bio-Path logo

About Bio-Path

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.63 out of 5 stars

Medical Sector

955th out of 1,352 stocks

Pharmaceutical Preparations Industry

467th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

Is Bio-Path a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bio-Path stock.
View analyst ratings for Bio-Path
or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Path?

Wall Street analysts have given Bio-Path a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Path wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest in August. As of August 31st, there was short interest totaling 221,300 shares, an increase of 138.5% from the August 15th total of 92,800 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 3.2% of the company's shares are short sold.
View Bio-Path's Short Interest

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Bio-Path

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) issued its earnings results on Friday, May, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.07.
View Bio-Path's earnings history

How has Bio-Path's stock price been impacted by COVID-19 (Coronavirus)?

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BPTH stock has increased by 12.6% and is now trading at $5.35.
View which stocks have been most impacted by COVID-19

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Shares of Bio-Path reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for BPTH?

2 Wall Street analysts have issued 12-month price targets for Bio-Path's shares. Their forecasts range from $12.00 to $13.00. On average, they anticipate Bio-Path's stock price to reach $12.50 in the next year. This suggests a possible upside of 133.6% from the stock's current price.
View analysts' price targets for Bio-Path
or view top-rated stocks among Wall Street analysts.

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:
  • Peter H. Nielsen, Chairman, President, CEO, CFO, Treasurer & CAO
  • Ana Tari Ashizawa, Senior VP-Research, Development & Clinical Design
  • Anthony Price, Senior VP-Finance, Accounting & Administration
  • Douglas P. Morris, Secretary & Non-Independent Director
  • William F. Hahne, Vice President-Clinical Research

Who are some of Bio-Path's key competitors?

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.15%), Geode Capital Management LLC (0.94%), Dimensional Fund Advisors LP (0.40%), Citadel Advisors LLC (0.36%), Northern Trust Corp (0.25%) and State Street Corp (0.17%).
View institutional ownership trends for Bio-Path

Which institutional investors are buying Bio-Path stock?

BPTH stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, State Street Corp, Dimensional Fund Advisors LP, Geode Capital Management LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Bio-Path
or or view top insider-buying stocks.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $5.35.

How much money does Bio-Path make?

Bio-Path has a market capitalization of $37.24 million. The company earns $-10,880,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

How many employees does Bio-Path have?

Bio-Path employs 10 workers across the globe.

What is Bio-Path's official website?

The official website for Bio-Path is

Where are Bio-Path's headquarters?

Bio-Path is headquartered at 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at (832) 742-1357 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.